Christina Curtis, PhD, MSc, a leader in cancer genomics at Stanford University, is applying her AI-driven research approaches that advanced breast cancer understanding to uncover osteosarcoma’s origins and new perspectives on therapy.
Stories of Progress, Inspiration & Support
Research & Breakthroughs
Innovation and studies to improve patient outcomes
Advances in genetic sequencing and unprecedented collaboration among research institutions are helping scientists better predict prognosis, track treatment response, and move closer to personalized therapies for osteosarcoma.
This year, OSI awarded more than $1.5 million to help advance new treatments for osteosarcoma.
With $15 million in funding, OSI and the broader osteosarcoma community, pediatric cancer foundations, and Break Through Cancer (BTC) have teamed up to bring BTC’s team-based approach to osteosarcoma, bringing together investigators from across the country and around the world.
Supported by the Osteosarcoma Institute and Ethos Discovery, the MIMIC trial evaluates a new method of removing lung metastases in dogs, providing insights that can directly inform human osteosarcoma treatment and drug development.
The U.S. Food and Drug Administration (FDA), the Osteosarcoma Institute (OSI), and others are coming together to shape the future of osteosarcoma clinical trials.
No results found.
Sign Up to Receive The Frontline
at vero eos et accusamus et iusto odio dignis simos duccimus qui blanditis
We never sell or share your information.
Your donation provides immediate and long-term support to osteosarcoma patients.